Hot Topics in NASH: Current Controversies and New Developments in Fatty Liver Disease

More Information

Better Every Day: Improving Adherence and Quality of Life in Patients with Growth Hormone Deficiency- CEU 2019 Enduring

Begin

Learning Objectives:

• Summarize the epidemiological statistics and current best practices in growth hormone management
• Incorporate approaches to improve adherence from shared-decision making to appropriate use of longer-acting growth hormone formulations
• Counsel appropriate patients on benefits of GHD during the transition period

Credits:
1.0 AMA PRA Category 1 Credits™
1.0 ABIM MOC

All Eyes on Thyroid Eye Disease: A Master Clinician Discussion on Managing TED- CEU 2019 Enduring

Begin

Learning Objectives:

• Understand current medical and surgical options for moderate thyroid eye disease
• Apply the appropriate management for ophthalmic emergencies in thyroid eye disease
• Prioritize their approach to thyroid eye disease based on the different effects of currently available surgical and medical treatments on the different manifestations of TED

Credits:
1.0 AMA PRA Category 1 Credits™
1.0 ABIM MOC

Challenging Cases: When and How to Use GLP-1 Agonists in Diabetes Management- CEU 2019 Enduring

Begin

Learning Objectives:

• Apply guidelines and algorithms on the initiation and treatment of pharmacotherapies for the management of type 2 diabetes.
• Devise individualized initiation and treatment plans for patients with type 2 diabetes that incorporates updated clinical information on GLP-1 agonist options and take into consideration indications, safety, and efficacy as well as diabetes complications or significant risk factors.

Credits:
1.0 AMA PRA Category 1 Credits™
1.0 ABIM MOC

Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline Educational Activity

Begin

Learning Objectives:

• Apply the clinical practice guideline recommendations for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2DM) in individuals at metabolic risk for developing these conditions.

Credits:
.50 AMA PRA Category 1 Credits™

A Patient Centered Approach to Hypophosphatemia: Diagnosis, Evaluation, and Treatment

Begin

Learning Objectives:

• Incorporate best practices for evaluating and diagnosing patients with hypophosphatemia in their practice.
• Discuss pathophysiology and treatment strategies for patients with FGF-23 mediated phosphate disorders.
• Discuss pathophysiology and treatment strategies for patients with non-FGF-23 mediated phosphate disorders.

Credits:
2.0 AMA PRA Category 1 Credits™
2.0 ABIM MOC

Meeting The Needs of Patients, Not LDL-C Goals: The Role Of PCSK9 Inhibitors

Begin

Learning Objectives:

• Summarize the biology and genetic underpinnings of dyslipidemia as related to the LDL receptor.
• Discuss and identify lipid lowering therapies beyond traditional therapeutics like statins.
• Recognize the benefit of including PCSK9 inhibitors in the treatment of patients with ASCVD or FH.
• Assess the clinical trial evidence for the efficacy and safety of PCSK9 inhibitors in patients with statin intolerance.
• Review the cardiovascular risk reduction provided by PCSK9 inhibitors in combination with statin therapy.

Credits:
2.0 AMA PRA Category 1 Credits™
2.0 ABIM MOC

Beyond A1C: Type 1 Diabetes Care and Management

Begin

Learning Objectives:

• Devise individualized insulin therapy strategies to manage individuals with T1D
• Incorporate diabetes technology into treatment strategies for appropriate individuals with T1D
• Recognize and evaluate individuals with T1D for signs of microvascular disease
• Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve hypoglycemia prevention and exercise management

Credits:
6.0 AMA PRA Category 1 Credits™
6.0 ABIM MOC

Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline Educational Activity

Begin

Learning Objectives:

• Diagnose central precocious puberty in male childhood cancer survivors exposed to gonadotoxic therapy.
• Explain how GH deficiency and central precocious puberty may occur together, making it difficult to interpret linear growth data.
• Diagnose non–GH-related causes of growth failure such as spinal irradiation.
• Accurately interpret thyroid function tests in patients at risk for primary and central hypothyroidism.
• Explain the importance of the synergistic action of GH and sex hormones in the growing adolescent.
• Explain the risk for exacerbation of the symptoms of adrenal insufficiency in individuals on thyroid replacement and untreated central adrenal insufficiency.

Credits:
0.5 AMA PRA Category 1 Credits™